Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years

J Pediatr Surg. 2012 Jul;47(7):1331-9. doi: 10.1016/j.jpedsurg.2011.11.073.

Abstract

Background/purpose: The aim of the study was to analyze changing management and survival of children with hepatoblastoma (HBL) treated in one center.

Materials and methods: Over the last 20 years, 51 children with HBL were treated. Surgery was performed in 48 children (94.1%), conventional liver resection in 38 (of those, 2 received a rescue liver transplantation [LTx] for relapse), and total hepatectomy and primary LTx in 10 patients. The remaining 3 patients received only palliative treatment. Patient data were analyzed for survival with respect to PRETreatment EXTent of disease (PRETEXT), metastases, histopathology, conventional resection, and LTx.

Results: Survival of children with HBL treated with liver resection is 71% and 80% for primary LTx. Favorable prognostic factors for patient survival was tumor histology as epithelial-fetal subtype and mixed epithelial and mesenchymal type, without teratoid features, and good response to chemotherapy (necrosis, fibrosis). Unfavorable prognostic factors were small cells undifferentiated, transitional liver cell tumor, α-fetoprotein level above 1,000,000 IU/mL and below 100 IU/mL at diagnosis, lung metastases, and local recurrence after initial resection. Survival was related to PRETEXT stage. However, among patients with PRETEXT III and IV, LTx resulted in better survival.

Conclusion: Liver transplantation is a good option for children with advanced HBL. Early referral of children with potentially unresectable tumors to centers where combined treatment (chemotherapy, surgery including LTx) is available is crucial.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Cisplatin / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Follow-Up Studies
  • Hepatectomy / methods
  • Hepatectomy / trends*
  • Hepatoblastoma / drug therapy
  • Hepatoblastoma / mortality
  • Hepatoblastoma / surgery*
  • Humans
  • Infant
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery*
  • Liver Transplantation / methods
  • Liver Transplantation / trends*
  • Male
  • Neoadjuvant Therapy
  • Palliative Care
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • Cisplatin

Supplementary concepts

  • AP protocol 1